
BioMarin’s experimental hemophilia gene therapy, which is expected to be approved by U.S. regulators in August, has continued to prevent bleeding in patients treated four years ago.
However, levels of the key clotting protein the treatment helps produce, Factor VIII, continued to slowly decline, potentially leading to questions as to how long-lasting the benefits might be.